BR112017017505A2 - derivados de quinolina para uso no tratamento ou prevenção de infecções virais - Google Patents
derivados de quinolina para uso no tratamento ou prevenção de infecções viraisInfo
- Publication number
- BR112017017505A2 BR112017017505A2 BR112017017505-3A BR112017017505A BR112017017505A2 BR 112017017505 A2 BR112017017505 A2 BR 112017017505A2 BR 112017017505 A BR112017017505 A BR 112017017505A BR 112017017505 A2 BR112017017505 A2 BR 112017017505A2
- Authority
- BR
- Brazil
- Prior art keywords
- hiv
- treatment
- prevention
- patient
- infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção se refere a um derivado de quinolina de fórmula (i) ou qualquer um dos seus sais farmaceuticamente aceitáveis, ou qualquer um dos seus metabólitos, para uso no tratamento ou prevenção de uma infecção viral, em particular uma infecção por hiv ou uma condição relacionada com o hiv num paciente e, em seguida, em que o referido tratamento é encerrado quando: a carga viral é baixa ou indetectável; e / ou o nível de contagem de células cd4+ é mantido ou restaurado. a presente invenção se refere ainda a um derivado de quinolina de fórmula (i) como definido na reivindicação 1, ou qualquer um dos seus sais e metabólitos farmaceuticamente aceitáveis, para utilização para tratamento ou prevenção de uma infecção viral, em particular uma infecção por hiv ou uma condição relacionada com o hiv num paciente, em que uma ineficácia ou um declínio em termos de eficácia em uma tratamento anti-retroviral prévio foi reportado e a um derivado de quinolina de fórmula (i) tal como definido acima, ou qualquer um dos seus sais farmaceuticamente aceitáveis e metabólitos, para uso no tratamento ou prevenção de uma infecção viral, em particular uma infecção por hiv ou de uma condição relacionada com o hiv em um doente, em que o paciente é infectado com uma cepa viral fármaco-resistente, e mais particularmente por uma cepa de hiv fármaco-resistentes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305277.4A EP3058940A1 (en) | 2015-02-23 | 2015-02-23 | Quinoline derivatives for use in the treatment or prevention of viral infection |
| EP15305277.4 | 2015-02-23 | ||
| PCT/EP2016/053535 WO2016135055A1 (en) | 2015-02-23 | 2016-02-19 | Quinoline derivatives for use in the treatment or prevention of viral infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017017505A2 true BR112017017505A2 (pt) | 2018-04-17 |
Family
ID=52629499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017017505-3A BR112017017505A2 (pt) | 2015-02-23 | 2016-02-19 | derivados de quinolina para uso no tratamento ou prevenção de infecções virais |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10806729B2 (pt) |
| EP (2) | EP3058940A1 (pt) |
| JP (1) | JP6826988B2 (pt) |
| KR (1) | KR102650958B1 (pt) |
| CN (1) | CN107635559A (pt) |
| AU (1) | AU2016223599B2 (pt) |
| BR (1) | BR112017017505A2 (pt) |
| CA (1) | CA2975777C (pt) |
| DK (1) | DK3261642T3 (pt) |
| ES (1) | ES2882542T3 (pt) |
| HR (1) | HRP20211172T1 (pt) |
| HU (1) | HUE055592T2 (pt) |
| LT (1) | LT3261642T (pt) |
| MX (2) | MX2017010623A (pt) |
| PL (1) | PL3261642T3 (pt) |
| PT (1) | PT3261642T (pt) |
| RS (1) | RS62173B1 (pt) |
| RU (1) | RU2723016C2 (pt) |
| SI (1) | SI3261642T1 (pt) |
| WO (1) | WO2016135055A1 (pt) |
| ZA (1) | ZA201705634B (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP3594205A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
| EP3594206A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| EP3669873A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| CA3158591A1 (en) * | 2019-11-26 | 2021-06-03 | Carolyn Luscombe | Methods of treating hiv-1 infection |
| KR102399037B1 (ko) * | 2020-01-06 | 2022-05-17 | 성균관대학교산학협력단 | 아민화된 아진의 신규한 제조방법 |
| EP3884946A1 (en) * | 2020-03-25 | 2021-09-29 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| CA3172179A1 (en) * | 2020-03-20 | 2021-09-23 | Jamal Tazi | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| EP3881844A1 (en) * | 2020-03-20 | 2021-09-22 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| WO2023126951A1 (en) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibitors of autophagy-related protein-protein interactions |
| CN114931580B (zh) * | 2022-05-26 | 2024-04-19 | 军事科学院军事医学研究院军事兽医研究所 | 依曲韦林在抗狂犬病病毒中的应用和抗狂犬病病毒药物的筛选方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5354853A (en) * | 1993-03-12 | 1994-10-11 | Genzyme Corporation | Phospholipid-saccharide conjugates |
| MX359575B (es) * | 2009-06-12 | 2018-10-03 | Abivax | Compuestos utiles para tratar sida. |
| EP2465502A1 (en) * | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| EP2757161A1 (en) * | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| ES2898385T3 (es) * | 2013-07-05 | 2022-03-07 | Abivax | Compuestos bicíclicos útiles para el tratamiento de enfermedades causadas por retrovirus |
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
-
2015
- 2015-02-23 EP EP15305277.4A patent/EP3058940A1/en not_active Withdrawn
-
2016
- 2016-02-19 PT PT167059294T patent/PT3261642T/pt unknown
- 2016-02-19 AU AU2016223599A patent/AU2016223599B2/en active Active
- 2016-02-19 SI SI201631277T patent/SI3261642T1/sl unknown
- 2016-02-19 HR HRP20211172TT patent/HRP20211172T1/hr unknown
- 2016-02-19 CN CN201680011581.6A patent/CN107635559A/zh active Pending
- 2016-02-19 MX MX2017010623A patent/MX2017010623A/es unknown
- 2016-02-19 JP JP2017544314A patent/JP6826988B2/ja active Active
- 2016-02-19 RS RS20210964A patent/RS62173B1/sr unknown
- 2016-02-19 CA CA2975777A patent/CA2975777C/en active Active
- 2016-02-19 US US15/552,921 patent/US10806729B2/en active Active
- 2016-02-19 RU RU2017128644A patent/RU2723016C2/ru active
- 2016-02-19 LT LTEP16705929.4T patent/LT3261642T/lt unknown
- 2016-02-19 KR KR1020177026021A patent/KR102650958B1/ko active IP Right Grant
- 2016-02-19 EP EP16705929.4A patent/EP3261642B1/en active Active
- 2016-02-19 WO PCT/EP2016/053535 patent/WO2016135055A1/en active Application Filing
- 2016-02-19 DK DK16705929.4T patent/DK3261642T3/da active
- 2016-02-19 ES ES16705929T patent/ES2882542T3/es active Active
- 2016-02-19 BR BR112017017505-3A patent/BR112017017505A2/pt not_active Application Discontinuation
- 2016-02-19 PL PL16705929T patent/PL3261642T3/pl unknown
- 2016-02-19 HU HUE16705929A patent/HUE055592T2/hu unknown
-
2017
- 2017-08-17 MX MX2021006636A patent/MX2021006636A/es unknown
- 2017-08-18 ZA ZA2017/05634A patent/ZA201705634B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016223599B2 (en) | 2021-03-11 |
| DK3261642T3 (da) | 2021-08-09 |
| AU2016223599A1 (en) | 2017-08-31 |
| US10806729B2 (en) | 2020-10-20 |
| PT3261642T (pt) | 2021-08-02 |
| CA2975777A1 (en) | 2016-09-01 |
| SI3261642T1 (sl) | 2021-10-29 |
| MX2017010623A (es) | 2018-03-12 |
| HRP20211172T1 (hr) | 2021-12-24 |
| CN107635559A (zh) | 2018-01-26 |
| CA2975777C (en) | 2022-12-13 |
| EP3261642A1 (en) | 2018-01-03 |
| KR20170125850A (ko) | 2017-11-15 |
| EP3261642B1 (en) | 2021-05-19 |
| RU2723016C2 (ru) | 2020-06-08 |
| ES2882542T3 (es) | 2021-12-02 |
| MX2021006636A (es) | 2021-07-07 |
| US20180028522A1 (en) | 2018-02-01 |
| KR102650958B1 (ko) | 2024-03-22 |
| JP2018505909A (ja) | 2018-03-01 |
| JP6826988B2 (ja) | 2021-02-10 |
| RU2017128644A (ru) | 2019-03-25 |
| HUE055592T2 (hu) | 2021-12-28 |
| RS62173B1 (sr) | 2021-08-31 |
| ZA201705634B (en) | 2018-12-19 |
| PL3261642T3 (pl) | 2021-11-15 |
| LT3261642T (lt) | 2021-07-26 |
| EP3058940A1 (en) | 2016-08-24 |
| RU2017128644A3 (pt) | 2019-04-15 |
| WO2016135055A1 (en) | 2016-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017017505A2 (pt) | derivados de quinolina para uso no tratamento ou prevenção de infecções virais | |
| CO2019001379A2 (es) | Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih . | |
| CU20150096A7 (es) | Compuestos de amida y composición farmacéutica para el tratamiento de vih | |
| UY37710A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| UA114006C2 (xx) | Похідні 5-фенокси-3h-піримідин-4-ону і їхнє застосування як інгібіторів зворотної транскриптази віл | |
| TR201909152T4 (tr) | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımı. | |
| EA201791872A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| BR112017017500A2 (pt) | derivado de quinolina para uso no tratamento e prevenção de infecções virais | |
| PH12015501445B1 (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| CL2015001864A1 (es) | Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih. | |
| EA201690687A1 (ru) | Ингибиторы репликации вируса иммунодефицита | |
| PH12015501156A1 (en) | Pharmaceutical compositions | |
| BR112018002689A2 (pt) | composto, composição útil e método para tratamento de infecção por hiv | |
| EP3757105A3 (en) | Polycyclic pyridone derivative having integrase inhibitory activity | |
| IN2014MN01548A (pt) | ||
| MX2021004593A (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. | |
| PH12016500465A1 (en) | Deoxynojirimycin derivatives and methods of their using | |
| BR112017028456A2 (pt) | composto, e, método de prevenção e/ou tratamento de hiv | |
| BR112018015629A2 (pt) | ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla? | |
| BR112018003181A2 (pt) | composto, composição, e, método para tratar infecção por hiv | |
| BR112018002678A2 (pt) | composto, composição, e, método para tratar infecção por hiv | |
| MX2021015441A (es) | Formas cristalinas de cabotegravir de sodio. | |
| BR112018000253A2 (pt) | composto, composição, e, método para tratar a infecção pelo hiv. | |
| BR112018000251A2 (pt) | composto, composição, e, método para tratar a infecção pelo hiv. | |
| BR112018000179A2 (pt) | composto, composição, e, método para tratar a infecção pelo hiv. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |